Karyopharm Therapeutics Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Karyopharm Therapeutics Inc. (KPTI) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $2.00 thousand as of 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2026-02-13
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $2.00K.
- 2024-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $5.00K.
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $115.00K.
- 2024-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $126.00K.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2024-12-31 | $2.00K 10-K · filed 2026-02-13 |
| 2024-09-30 | $5.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $115.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $126.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $152.00K 10-K · filed 2025-02-19 |
| 2023-09-30 | $425.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $580.00K 10-Q · filed 2023-08-02 |
| 2023-03-31 | $334.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $348.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $332.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $186.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $21.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $9.00K 10-K · filed 2023-02-17 |
| 2021-09-30 | $7.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $9.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $42.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $46.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $33.00K 10-Q · filed 2020-11-02 |
| 2020-06-30 | $43.00K 10-Q · filed 2020-08-04 |
| 2020-03-31 | $535.00K 10-Q · filed 2020-05-05 |
| 2019-12-31 | $44.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |